Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 42

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 42
---
 Amgen where he led the R&D activities for the Biosimilar Business Unit and held multiple roles from 2006 to 2019 including as Clinical Development Medical Director and served as pre-launch Medical Affairs Lead for denosumab (XGEVA®), for patients with bone metastases from prostate cancer, breast cancer and other solid tumors. Prior to Amgen, Dr. Markus was Sr. Medical Director at Corus Pharma, where he led the phase 2 and phase 3 development of Cayston®. Dr. Markus received his B.S. degree in Cybernetics from UCLA and his M.D. and Ph.D. at the University of Southern California.

Carolyn Tang has served as our General Counsel since September 2019, after joining Arcus in 2017. From 2015 to 2017, Ms. Tang was Director of Securities and Transactions at Medivation, Inc., a biopharmaceutical company, where she was responsible for securities, corporate governance and strategic transactions until the company’s acquisition by Pfizer, Inc. From 2004 to 2015, Ms. Tang was at InterMune, Inc., a biotechnology company focused on pulmonology and orphan fibrotic diseases, ultimately having responsibility for the company’s global intellectual property portfolio and transactions, and supporting the company’s corporate and securities activities until its acquisition by Roche Holdings, Inc. Ms. Tang received her law degree from Santa Clara University School of Law and her B.A. in Molecular and Cell Biology, with an emphasis in Neurobiology, from the University of California at Berkeley.

<div align='center'>23.</div>

### EXECUTIVE COMPENSATION

### Compensation Discussion and Analysis
This Compensation Discussion and Analysis provides an overview of the material components of our executive compensation program for the year ended December 31, 2024, for named executive officers, whose compensation is set forth in the Summary Compensation Table and other compensation tables contained in this Proxy Statement. For the year ended December 31, 2024, our “named executive officers” are:

• Terry Rosen, Ph.D., our Chief Executive Officer;

• Robert C. Goeltz, our Chief Financial Officer;

• Juan C. Jaen, Ph.D., our President;

• Jennifer Jarrett, our Chief Operating Officer; and

• Dimitry S.A. Nuyten, M.D., Ph.D., our former Chief Medical Officer.

Dr. Nuyten ceased serving as our Chief Medical Officer on January 31, 2025.

This